Linnaeus Therapeutics, Inc.
Clinical trials sponsored by Linnaeus Therapeutics, Inc., explained in plain language.
-
New pill plus immunotherapy takes on tough melanoma
Disease control Recruiting nowThis study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, …
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill plus immunotherapy shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …
Phase: PHASE1, PHASE2 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC